• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Development of Anti-Idiotype Monoclonal Antibodies for the Treatment of BreastCancer
【24h】

Development of Anti-Idiotype Monoclonal Antibodies for the Treatment of BreastCancer

机译：用于治疗乳腺癌的抗独特型单克隆抗体的研制

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

For the development of HER2/neu mimicking anti-idiotype antibodies (Ab2s), groupsof female BALD/c mice were immunized with three sets of monoclonal antibodies (Ab1), designated 520C9, 741F8 and 454C11, directed at distinct antigenic determinants of HER2/neu. Hybridomas were generated from each treatment group and one, stable Ab2 producing hybrid each of 520C9 and 741F8 were obtained, and cloned twice by limiting dilution. The isotypes of 520C9 and 741F8 Ab2's were IgG1k by ELISA. 520C9 and 741F8 Ab2 cells were used to produce mouse ascites and the Ab2 purified by affinity chromatography and confirmed by SDS-PAGE. A competitive binding assay using Ab2, Ab1 and the human breast cancer cell line SK-BR-3 (which express HER2/neu on their cell surface), showed that 50mu1 of each of 520C9 and 741F8 Ab2 containing supernatants inhibited the binding of Ab1 to SK-BR-3 cells by tilde 80%.The specificity binding study showed that the binding of 741F8 Ab2 was to those antibodies directed against HER/2neu. A competitive binding assay using 741F8 Ab2, Ab1 and SK-BR-3 cells showed that 10ng of purified 741F8 Ab2 inhibited the binding of Ab1 to SK-BR-3 cells by tilde 50%. Polyclonal anti-anti-idiotype antibodies (Ab3), were generated in rabbits using either purified 520C9 Ab2 or 741F8 Ab2. The Ab3 reacted with HER2/neu positive tumor cells suggesting the presence of anti-tumor (Ab1') antibodies.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号